In and out products to enhance skin beauty and longevity
The wall between cosmetics and nutrition is dissolving
For decades, the skincare industry and the supplement industry operated as separate worlds. They served the same consumer, often with the same botanical species, but through entirely different supply chains, regulatory frameworks, and product development cultures. A cosmetics formulator sourcing Centella asiatica extract for a serum had no reason to coordinate with the nutraceutical team sourcing Centella for a cognitive health capsule, even within the same company.
That separation is breaking down. A growing number of brands are building integrated product strategies where the same botanical active appears in both a topical product and an ingestible product, designed to work together. The industry calls this In and Out. In the nutricosmetics segment, which sits at the intersection of beauty and health, this approach is becoming a defining product development strategy.
What is driving the convergence
The underlying driver is a shift in how consumers understand health and beauty. The idea that skin health is connected to nutrition, stress, sleep, and gut function is no longer alternative thinking. It is mainstream. The beauty from within movement has crossed from niche wellness into mass market positioning. Consumers increasingly expect brands to address these connections, not just acknowledge them in marketing copy but build product lines that reflect them.
For brands, this creates both an opportunity and a constraint. The opportunity is product line coherence: a Centella serum paired with a Centella supplement creates a story that is more compelling and more defensible than either product alone. The constraint is that the In and Out approach requires the same botanical ingredient to meet multiple regulatory standards simultaneously. A topical product in Europe falls under EC 1223/2009 (Cosmetics Regulation). An ingestible product falls under the Food Supplements Directive (2002/46/EC) and, if health claims are involved, the Nutrition and Health Claims Regulation. A pharmaceutical application adds a further layer under national medicines agency requirements. For certain botanical species, the ingestible product may also require Novel Food authorization under EU 2015/2283 if the species lacks a documented history of consumption in the EU prior to 1997. The same raw material must satisfy whichever combination of these frameworks applies.
The supply chain problem this creates
In a traditional sourcing model, a brand building an In and Out or nutricosmetics strategy would need to qualify two separate suppliers, or qualify the same supplier under two separate sets of documentation, or accept the risk that their topical-grade and ingestible-grade ingredients, sourced from different supply chains, have different phytochemical profiles. None of these options is efficient, and the third option actively undermines the coherence that an In and Out strategy depends on.
The issue is not just documentation. It is consistency. If the Centella extract in the serum has one triterpenic acid profile and the Centella powder in the supplement has a different profile, the In and Out story collapses at the analytical level. The consumer may not notice, but the formulation team will, and any regulatory reviewer comparing product dossiers across the two categories certainly will.
What a single-source model solves
When both the topical and ingestible ingredients come from the same cultivation system, the same genetic stock, and the same quality management infrastructure, the consistency problem disappears. The Centella in the serum and the Centella in the capsule share the same phytochemical fingerprint because they come from the same plant, grown under the same conditions, processed through the same documented protocols.
This also simplifies regulatory documentation. A single supplier dossier, covering cultivation method, analytical specifications, contaminant screening, and traceability, serves cosmetics, food supplement, and pharmaceutical regulatory submissions simultaneously. The brand does not need to reconcile multiple sets of supplier documentation or explain discrepancies between them.
For species where root compounds are relevant to both applications, controlled-environment cultivation adds another dimension. Aeroponic systems provide access to root biomass that field cultivation cannot reliably deliver, opening formulation possibilities that span both topical and oral delivery with the same root-derived actives.
How supplier evaluation is changing
The In and Out trend is still early, but it is moving fast enough to change how procurement teams evaluate botanical suppliers. The question is no longer just whether a supplier can deliver a species at a given specification. It is whether that supplier can deliver the same species, at the same specification, in formats suitable for cosmetics, nutraceutical, and pharmaceutical applications, supported by documentation that satisfies all three regulatory frameworks. As nutricosmetics moves from emerging category to established market segment, procurement teams building their 2027 supplier shortlists are treating this as a practical evaluation criterion, not a theoretical one.
